What are the considerations for Holmium Laser Enucleation of the Prostate (HoLEP) or Robotic-assisted HoLEP for a patient with a 150g prostate and symptoms of Benign Prostatic Hyperplasia (BPH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HoLEP for Large Prostates (150g)

For a patient with a 150g prostate and BPH symptoms, HoLEP is the optimal surgical choice and should be strongly recommended as the preferred treatment over robotic-assisted simple prostatectomy or other alternatives. 1, 2

Why HoLEP is the Best Option for This Patient

Size-Independent Gold Standard

  • HoLEP is explicitly recommended by both the AUA and EAU as a size-independent treatment option for moderate-to-severe LUTS, meaning it can be performed on prostates of any size without limitation, including very large prostates >80g like this 150g gland. 1, 2, 3
  • The EAU guidelines specifically state that HoLEP should be offered as an alternative to TURP or open prostatectomy with a strong recommendation for men with moderate-to-severe LUTS. 1
  • At 150g, this prostate is nearly double the threshold where traditional TURP becomes problematic, making HoLEP particularly advantageous. 1

Superior Long-Term Outcomes

  • HoLEP demonstrates durable symptomatic improvement with long-term data extending beyond 10 years, showing superior outcomes compared to TURP including greater Qmax improvement (4.36 mL/s better at 7 years) and lower reoperation rates. 4, 3
  • The reoperation rate for HoLEP at 3 years is 7.2%, comparable to TURP's 6.6%, but HoLEP's ability to completely enucleate all adenomatous tissue provides better durability for large prostates. 5
  • Patients achieve significant IPSS reduction and Qmax improvement that is sustained long-term, directly impacting quality of life. 4, 6

Safety Profile and Recovery

  • HoLEP offers excellent hemostatic properties, making it the safer choice for patients with high bleeding risk or those on anticoagulation/antiplatelet therapy. 1, 2
  • Patients benefit from significantly shorter catheterization times (median 2 days vs 5 days for robotic prostatectomy) and reduced hospital stay (median 3 days vs 4 days). 7, 8
  • The complication profile is favorable compared to open or robotic approaches, with lower rates of serious perioperative complications. 4, 6

What About Robotic-Assisted Simple Prostatectomy?

When RASP Might Be Considered

  • Robotic-assisted simple prostatectomy (RASP) is recommended by the AUA for large prostates when providers lack access to or expertise with HoLEP technology. 1
  • For extremely large prostates ≥200cc, RASP and HoLEP show similar functional outcomes with comparable improvements in Qmax (+10.6 vs +10.7 mL/s) and IPSS reduction. 7

Why HoLEP Still Wins at 150g

  • Despite similar efficacy, HoLEP provides shorter hospital stays and catheterization times even in prostates ≥200cc, making it preferable for this 150g prostate. 7, 8
  • A propensity-matched analysis showed that while trifecta outcomes (continence, Qmax >15, no complications) were similar between HoLEP (71.25%) and RASP (63.75%), HoLEP patients had significantly shorter postoperative stay and catheterization time. 8
  • The amount of tissue resected is actually greater with HoLEP (180g vs 134.5g in one study), suggesting more complete adenoma removal. 7

Robotic-Assisted HoLEP: Not Ready for Prime Time

  • There is no guideline support or high-quality evidence for robotic-assisted HoLEP in the provided literature. [1-8]
  • The established robotic approach for large prostates is RASP (simple prostatectomy), not robotic HoLEP. 1, 7
  • Standard HoLEP performed transurethrally remains the evidence-based approach with the most robust long-term data. 4, 3, 6

Clinical Algorithm for This Patient

Step 1: Confirm HoLEP Availability and Expertise

  • Verify that your institution has HoLEP capability and an experienced surgeon (the learning curve is steep but outcomes are superior once mastered). 4, 6
  • If HoLEP is available, proceed directly to recommending it as first-line surgical treatment. 1, 2

Step 2: If HoLEP Unavailable

  • Consider RASP as the next best alternative for this 150g prostate, given the size exceeds what is reasonable for TURP. 1, 7
  • Open simple prostatectomy remains an option but has higher morbidity than either HoLEP or RASP. 1

Step 3: Patient-Specific Considerations

  • If the patient is on anticoagulation or has high bleeding risk, HoLEP is strongly preferred over RASP due to superior hemostasis. 1, 2
  • If the patient prioritizes rapid recovery and shorter catheterization, HoLEP provides measurable advantages. 7, 8
  • Counsel regarding similar rates of retrograde ejaculation with both procedures (this is expected with complete adenoma removal). 4

Common Pitfalls to Avoid

Don't Default to RASP Just Because It's "Robotic"

  • The robotic platform does not confer superiority over standard HoLEP for BPH treatment. 7, 8
  • RASP requires longer catheterization and hospitalization without providing better functional outcomes. 7, 8

Don't Attempt TURP on This Size Prostate

  • At 150g, TURP would require prolonged resection time with increased complications and incomplete tissue removal. 1
  • The AUA guidelines acknowledge that while some providers achieve good results with transurethral approaches in prostates >60g, this requires specific expertise with bipolar TURP or HoLEP. 1

Don't Overlook the Learning Curve

  • HoLEP has a steeper learning curve than TURP, but appropriate mentoring and training overcome this barrier. 4, 6
  • Outcomes at high-volume centers with experienced surgeons are consistently superior to alternatives. 3, 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.